Sorafenib for relapsed FLT3‐ITD‐positive acute myeloid leukemia postallogeneic stem cell transplantation presenting as leukemia cutis
Abstract Relapse of FLT3‐mutated acute myeloid leukemia (AML) following allogeneic stem cell transplantation is associated with poor survival. The clinical utility of sorafenib monotherapy in this setting is described in a patient presenting as leukemia cutis.
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-12-01
|
| Series: | Clinical Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ccr3.2487 |